Log in

NASDAQ:SNOA - Sonoma Pharmaceuticals Stock Price, Forecast & News

+0.09 (+1.74 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
Now: $5.27
50-Day Range
MA: $5.15
52-Week Range
Now: $5.27
Volume46,675 shs
Average Volume15,781 shs
Market Capitalization$9.38 million
P/E RatioN/A
Dividend YieldN/A
Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SNOA



Sales & Book Value

Annual Sales$18.97 million
Book Value$6.31 per share


Net Income$-11,800,000.00


Market Cap$9.38 million
Next Earnings Date7/13/2020 (Estimated)
OptionableNot Optionable

Receive SNOA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.

Sonoma Pharmaceuticals (NASDAQ:SNOA) Frequently Asked Questions

What is Sonoma Pharmaceuticals' stock symbol?

Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) released its quarterly earnings data on Thursday, November, 14th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.18) by $0.27. The firm had revenue of $4.97 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 25.58% and a negative return on equity of 44.11%. View Sonoma Pharmaceuticals' Earnings History.

When is Sonoma Pharmaceuticals' next earnings date?

Sonoma Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July 13th 2020. View Earnings Estimates for Sonoma Pharmaceuticals.

Has Sonoma Pharmaceuticals been receiving favorable news coverage?

Media coverage about SNOA stock has been trending very negative on Saturday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sonoma Pharmaceuticals earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Sonoma Pharmaceuticals.

Are investors shorting Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals saw a drop in short interest in February. As of February 14th, there was short interest totalling 700 shares, a drop of 87.0% from the January 30th total of 5,400 shares. Based on an average trading volume of 27,200 shares, the short-interest ratio is presently 0.0 days. Approximately 0.1% of the shares of the stock are sold short. View Sonoma Pharmaceuticals' Current Options Chain.

Who are some of Sonoma Pharmaceuticals' key competitors?

What other stocks do shareholders of Sonoma Pharmaceuticals own?

Who are Sonoma Pharmaceuticals' key executives?

Sonoma Pharmaceuticals' management team includes the folowing people:
  • Mr. Frederick J. Sandford, CEO, Interim CFO & Director (Age 58)
  • Mr. Marc Umscheid, Chief Operating Officer (Age 50)
  • Dr. Robert Northey, Exec. VP of R&D (Age 62)
  • Mr. Bruce Thornton, Exec. VP of International Operations & Sales (Age 55)
  • Ms. Victoria Covel, Assistant Controller

Who are Sonoma Pharmaceuticals' major shareholders?

Sonoma Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.41%). Company insiders that own Sonoma Pharmaceuticals stock include James J Schutz and Robert E Miller. View Institutional Ownership Trends for Sonoma Pharmaceuticals.

Which major investors are buying Sonoma Pharmaceuticals stock?

SNOA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Sonoma Pharmaceuticals stock in the last two years include James J Schutz and Robert E Miller. View Insider Buying and Selling for Sonoma Pharmaceuticals.

How do I buy shares of Sonoma Pharmaceuticals?

Shares of SNOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sonoma Pharmaceuticals' stock price today?

One share of SNOA stock can currently be purchased for approximately $5.27.

How big of a company is Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals has a market capitalization of $9.38 million and generates $18.97 million in revenue each year. Sonoma Pharmaceuticals employs 78 workers across the globe.View Additional Information About Sonoma Pharmaceuticals.

What is Sonoma Pharmaceuticals' official website?

The official website for Sonoma Pharmaceuticals is http://www.sonomapharma.com/.

How can I contact Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals' mailing address is 1129 NORTH MCDOWELL BLVD., PETALUMA CA, 94954. The company can be reached via phone at 707-283-0550 or via email at [email protected]

MarketBeat Community Rating for Sonoma Pharmaceuticals (NASDAQ SNOA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  413
MarketBeat's community ratings are surveys of what our community members think about Sonoma Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNOA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNOA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel